Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphic Holding (MORF)
NASDAQ:MORF
Holding MORF?
Track your performance easily
MORF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.35 - $57.00
Previous Close$56.99
Volume1.80M
Average Volume (3M)2.44M
Market Cap
$2.86B
Enterprise Value$2.24B
Total Cash (Recent Filing)$628.37M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Oct 31, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding50,224,699
10 Day Avg. Volume1,555,856
30 Day Avg. Volume2,443,552
Standard Deviation0.21
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.31
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.29K
Enterprise Value/Ebitda-15.64
Forecast
1Y Price Target
$58.17Price Target Upside2.07% Upside
Rating ConsensusHold
Number of Analyst Covering9
Morphic Holding News
PremiumCompany Announcements
Morphic Holding Unveils Comprehensive Corporate Overhaul Post-Merger
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition of MORF ahead of the topline readout from the Phase 2b EMERALD-2 study in UC speaks to LLY’s confidence in MORF-057’s clinical profile and the commercial opportunity for a safe and effective oral therapy in IBD.
Market PotentialMORF-057's clean safety profile could see significant early line usage.
Strategic FitThe MORF acquisition is a strong strategic fit for LLY, which can leverage their resources and expertise in clinical development and commercial experience/infrastructure in IBD to maximize the value of MORF-057.
Bears Say
AcquisitionThe risk of another buyer at this stage is low given the premium Lilly has offered, and board commentary that the company was not put up for sale.
Stock RatingDowngrading shares of MORF to Market Perform following the announcement of Lilly's proposed acquisition.
Treatment PositioningThe position in the tx paradigm will be dependent on its final PBO-adjusted remission rate.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MORF FAQ
What was Morphic Holding’s price range in the past 12 months?
Morphic Holding lowest stock price was $19.34 and its highest was $57.00 in the past 12 months.
What is Morphic Holding’s market cap?
Currently, no data Available
When is Morphic Holding’s upcoming earnings report date?
Morphic Holding’s upcoming earnings report date is Oct 31, 2024 which is 52 days ago.
How were Morphic Holding’s earnings last quarter?
Morphic Holding released its earnings results on Jul 31, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.03 by -$0.12.
Is Morphic Holding overvalued?
According to Wall Street analysts Morphic Holding’s price is currently Undervalued.
Does Morphic Holding pay dividends?
Morphic Holding does not currently pay dividends.
What is Morphic Holding’s EPS estimate?
Morphic Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morphic Holding have?
Morphic Holding has 50,224,697 shares outstanding.
What happened to Morphic Holding’s price movement after its last earnings report?
Morphic Holding reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.03. Following the earnings report the stock price went down -0.194%.
Which hedge fund is a major shareholder of Morphic Holding?
Among the largest hedge funds holding Morphic Holding’s share is Perceptive Advisors LLC. It holds Morphic Holding’s shares valued at 10M.
---
Morphic Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.17 (2.07% Upside)
$58.17 (2.07% Upside)
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.72%
12-Months-Change
Fundamentals
Return on Equity
-26.68%
Trailing 12-Months
Asset Growth
-13.71%
Trailing 12-Months
Company Description
Morphic Holding
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
---
MORF Stock 12 Month Forecast
Average Price Target
$58.17
▲(2.07% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Meiragtx Holdings
―
Allogene Therapeutics
―
Best Analysts Covering MORF
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+25.02%
reiterated a buy rating 6 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +25.02% per trade.
---